Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EPS (Weighted Average and Diluted) (2019 - 2025)

Puma Biotechnology (PBYI) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.26 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 35.0% year-over-year to $0.26, compared with a TTM value of $0.61 through Dec 2025, down 1.61%, and an annual FY2025 reading of $0.61, down 1.61% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.26 for Q4 2025 at Puma Biotechnology, up from $0.17 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.41 in Q3 2024 and bottomed at -$1.09 in Q3 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.05, with a median of $0.08 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 1300.0% in 2023, then plummeted 433.33% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.1 in 2021, then plummeted by 230.0% to -$0.13 in 2022, then soared by 292.31% to $0.25 in 2023, then skyrocketed by 60.0% to $0.4 in 2024, then plummeted by 35.0% to $0.26 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PBYI at $0.26 in Q4 2025, $0.17 in Q3 2025, and $0.12 in Q2 2025.